Core Viewpoint - Cibus, Inc. has announced a public offering of 6,976,744 shares of its Class A Common Stock at a price of $2.15 per share, aiming to raise approximately $15 million for working capital and corporate purposes, particularly for the development of weed management traits in rice [1][3]. Group 1: Offering Details - The offering includes a 30-day option for the underwriter to purchase an additional 1,046,511 shares to cover over-allotments [2]. - The gross proceeds from the offering are expected to be around $15 million, or $17.2 million if the underwriter fully exercises its option [3]. - The offering is set to close on March 27, 2026, pending customary closing conditions [3]. Group 2: Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies, utilizing high-throughput gene editing technologies [7]. - The company is not a seed company but a technology firm that aims to enhance productivity traits for major global row crops at a lower cost and time compared to conventional breeding methods [7].

Core Viewpoint - Cibus, Inc. is initiating an underwritten public offering of its Class A common stock and pre-funded warrants, with the intention to use the proceeds for working capital and the development of weed management traits in rice [1][2]. Group 1: Offering Details - Cibus plans to offer shares of its Class A common stock and pre-funded warrants to certain investors [1]. - The underwriter, BTIG, LLC, will have a 30-day option to purchase up to an additional 15% of the shares offered [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, specifically to fund further development of weed management traits in rice [2]. Group 3: Regulatory Information - The securities will be offered under an effective shelf registration statement on Form S-3, filed with the SEC [3]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC and made available on their website [3]. Group 4: Company Overview - Cibus is a leader in developing traits that address productivity, yield, and sustainability challenges in agriculture [5]. - The company utilizes proprietary high-throughput gene editing technologies to develop plant traits more efficiently than conventional breeding methods [5].

Core Insights - Cibus is positioning rice as its primary near-term royalty opportunity, with seven customers in the U.S. and Latin America representing over $200 million in potential annual royalties from herbicide-tolerant traits [1][6] - The company anticipates market entry in Latin America by 2027, U.S. expansion in 2028, and entry into India and Asia around 2030 [1][6] - Cibus has transitioned to a commercially driven model, emphasizing that gene edits are the product and future value is linked to royalty streams from gene-edited traits [2][6] Regulatory Momentum - Cibus highlighted significant regulatory developments, including the EU's NGT agreement and the U.K.'s PBO framework, which are expected to accelerate commercial discussions [4][13] - The company noted that California has authorized gene-edited rice for planting, and Ecuador confirmed that Cibus' traits are equivalent to those developed through conventional breeding [15] Financial Position - As of year-end 2025, Cibus reported cash and cash equivalents of $9.9 million and raised $22.3 million in January 2026, extending its financial runway into late Q3 2026 [4][19] - The company aims to reduce annual net cash usage to approximately $30 million or less in 2026 through cost-cutting measures [20] Product Development and Partnerships - Cibus received its first customer payment from a sustainable ingredients program and expects commercial-scale production later this year, with potential annual royalties of $20–40 million when fully commercialized [5][11] - The company is expanding its rice trait stacking efforts to enhance weed management options and has established partnerships with Colombian rice seed companies [7][8] Technology and Efficiency - Cibus achieved significant improvements in rice editing efficiency in 2025, utilizing optimized reagents and AI to enhance target identification and predict edit outcomes [16] - The company is also advancing multiple pipeline programs, including canola and winter oilseed rape, with positive field trial results [17][24] Future Outlook - Management indicated that 2026 will focus on executing rice commercialization milestones in Latin America, expanding customer relationships, and formalizing sustainable ingredients partnerships [21]

Financial Performance - Cibus reported a quarterly loss of $0.42 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $0.87 per share a year ago, indicating an earnings surprise of +2.33% [1] - The company posted revenues of $1.06 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 27.85%, and down from $1.21 million in the same quarter last year [2] Stock Performance - Cibus shares have increased by approximately 104.6% since the beginning of the year, contrasting with a 2.1% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.36 on revenues of $1.92 million, and for the current fiscal year, it is -$1.30 on revenues of $7.78 million [7] Industry Outlook - The Agriculture - Operations industry, to which Cibus belongs, is currently ranked in the bottom 18% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Cibus's stock performance [5]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company's cash and cash equivalents were $9.9 million, and in January 2026, it raised $22.3 million in gross proceeds from a public offering, extending its runway for operations [24][25] - The net loss for the fourth quarter of 2025 was $31.9 million, compared to $25.8 million in the same period the previous year [27] - Research and development expenses decreased to $9.4 million from $12.4 million year-over-year, while selling, general, and administrative expenses fell to $5.1 million from $6.8 million [25][26] Business Line Data and Key Metrics Changes - The rice program remains a core revenue generator, with seven rice customers representing a potential annual royalty opportunity of over $200 million [9][48] - The sustainable ingredients program has completed pre-commercial pilot runs for two biofragrance products, leading to the first customer payment in Q4 2025, with potential annual royalties estimated between $20 million and $40 million [15][16] Market Data and Key Metrics Changes - The company is targeting 5-7 million acres in the Americas for its rice traits, with potential expansion into India, which has approximately 120 million acres of rice cultivation [46][48] - The EU's recent political agreement on New Genomic Techniques legislation opens up approximately 100 million acres of greenfield opportunity in Europe, which has historically restricted GMO technologies [17][35] Company Strategy and Development Direction - The company is transitioning to a commercially driven model, focusing on gene editing as a core technology for agricultural innovation [4][5] - Cibus aims to build long-term shareholder value through a licensing and royalty framework tied to its gene editing capabilities, emphasizing ongoing relationships with seed companies [8][9] - The company is expanding its partnerships in Latin America and India, with plans for commercial launches in 2027 and 2030, respectively [10][12] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a pivotal year focused on execution and momentum, with expectations for significant advancements in rice commercialization and sustainable ingredients [29][30] - The regulatory landscape is evolving positively, with the EU's new legislation expected to catalyze commercial opportunities and partnerships [17][30] Other Important Information - The company has streamlined operations, reducing annual net cash usage to approximately $30 million or less in 2026, which supports its focus on near-term revenue [27][66] - The company has consolidated operations from its Oberlin facility into its San Diego headquarters, which is part of its cost-saving initiatives [27] Q&A Session Summary Question: Impact of EU NGT framework on CapEx for canola WOSR program - Management highlighted that the EU regulatory progress opens up significant opportunities for gene editing in Europe, particularly for winter oilseed rape, which is a major crop [34][35] Question: Next steps for rice commercialization in Latin America - Management outlined the process of editing elite genetics and the partnership with Interoc for commercialization in Ecuador and Colombia, with a focus on chemical registration and trait work [38][40] Question: Trend line for acres touched by technology - Management indicated a target of 5-7 million acres in the Americas, with potential for an additional 200 million acres in India by the end of the decade [46][48] Question: Maximum throughput for gene edits as a service - Management discussed the scalability of their gene editing platform, emphasizing the efficiency gained through automation and AI, which allows for managing multiple crops and lines [50][53] Question: Royalty rates for gene edits as a service - Management noted that the speed and scalability of their gene editing process allow for favorable negotiations on trait royalties, as customers can see value added quickly [56] Question: Scale of fragrance projects - Management mentioned the potential to work on approximately 17 fragrances, with plans to accelerate the process once the initial products are commercialized [57]

Financial Data and Key Metrics Changes - As of December 31, 2025, cash and cash equivalents were $9.9 million, with a subsequent capital raise of $22.3 million in January 2026, extending the company's runway [22][23] - Operating expenses were reduced by approximately $10 million across R&D and SG&A for the full year of 2025, with R&D expenses at $9.4 million and SG&A at $5.1 million for Q4 2025, down from $12.4 million and $6.8 million respectively in the prior year [23][24] - The net loss for Q4 2025 was $31.9 million, compared to $25.8 million in the same period last year [24] Business Line Data and Key Metrics Changes - The rice program is projected to generate $200 million in potential annual royalty opportunities through herbicide-tolerant traits, with initial market entry in Latin America expected in 2027 [9][10] - The sustainable ingredients program has completed pre-commercial pilot runs for two biofragrance products, leading to the first payment in Q4 2025, with potential annual royalties estimated between $20 million and $40 million [14][15] Market Data and Key Metrics Changes - The EU's political agreement on New Genomic Techniques legislation opens up approximately 100 million acres of greenfield opportunity, significantly impacting the gene editing market [16] - The company is targeting 5-7 million acres in the Americas for its rice traits, with potential expansion into the Indian market, which encompasses around 120 million acres [44] Company Strategy and Development Direction - The company is transitioning to a commercially driven model, focusing on gene editing as a core technology for agricultural innovation [5][6] - Cibus aims to serve as a gene editing engine for plant breeding capabilities, moving beyond traditional trait licensing to establish ongoing genomic editing relationships with seed companies [6][8] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a year focused on execution and momentum, with plans to expand customer relationships and advance commercialization agreements [27] - The regulatory landscape is evolving positively, with significant developments in Europe and the Americas that are expected to accelerate commercial conversations globally [16][27] Other Important Information - The company has consolidated operations from its Oberlin facility into its San Diego headquarters, which is part of a broader effort to streamline operations and reduce cash usage [24][25] - The advancements in gene editing technology have led to improved efficiency and scalability, enabling the company to respond to market demands more effectively [18][46] Q&A Session Summary Question: Impact of EU NGT framework on CapEx and canola program - Management highlighted the EU regulatory progress as a watershed moment, opening up significant opportunities for crops like winter oilseed rape, which is a major crop in Europe [32][33] Question: Next steps for rice commercialization in Latin America - The company outlined the process of editing elite genetics and the partnership with Interoc for commercialization in Ecuador and Colombia, with a focus on chemical registration and trait work [36][38] Question: Trend line for acres touched by technology - Management indicated a target of 5-7 million acres in the Americas, with potential for additional revenue from the Indian market in the future [44] Question: Scale of gene editing services - The company emphasized its efficient production system and automation, which allows for rapid scaling of gene editing services without significant increases in R&D expenses [46][49] Question: Royalty rates for gene edits as a service - Management noted that the speed and scalability of their gene editing process allow for favorable negotiations on trait royalties, as customers can see value added quickly [51][52] Question: Scale of fragrance projects - The company is currently focused on a few fragrances but sees potential to scale quickly, targeting around 17 fragrances for future development [53]

Financial Outlook - Cibus anticipates significant losses will continue for several years, relying on additional near-term financing to maintain operations[16]. - The company expects to reduce annual net cash usage to approximately $30 million or less in 2026 due to workforce reductions and streamlining efforts[30]. - Cibus estimates one-time cash payments of approximately $0.4 million related to workforce reductions in Q1 2026, alongside a non-cash stock compensation expense of about $0.5 million[30]. - Cibus' financial statements include goodwill, which may become impaired under certain conditions, affecting financial results[17]. Market Potential - The global seed market's aggregate trait value is estimated at approximately $12.0 billion, with Cibus focusing on plant traits that enhance productivity and sustainability[25][26]. - Cibus' Rice herbicide tolerance traits have an estimated potential annual addressable royalty of over $200.0 million upon full commercialization in target markets[26]. - Cibus estimates potential annual addressable royalties for its Sclerotinia resistance trait in Soybean could exceed $500 million, with a peak addressable market of 50 million acres[31]. - The global fragrance market is valued at over $65 billion, presenting significant long-term opportunities for Cibus' biofragrance products developed through gene editing[72]. Research and Development - Cibus has successfully completed greenhouse trials for its gene-edited traits in Rice, Canola, and Soybean, with ongoing progress in field trials for Soybean[37]. - Cibus' R&D is focused on developing crop-specific platforms and gene editing technologies, integral to its Trait Machine process[193]. - Cibus' Trait Machine process enables rapid prototyping and commercialization of new traits, significantly reducing the time to market compared to conventional breeding methods[87]. - Cibus' RTDS technology platform allows for rapid and efficient gene editing, significantly changing the scale and speed of trait development and commercialization[131]. Regulatory Environment - Regulatory changes regarding gene editing could significantly impact Cibus' ability to develop and commercialize its products[17]. - The EU's new regulatory framework for gene-edited plants is expected to be published in 2026, potentially constraining access to European acres for Cibus' weed management traits[50]. - The FDA has cleared Cibus' altered lignin alfalfa trait for commercialization in the US, expected to launch the first two commercial gene edited varieties in the next few years[81]. - Cibus has received regulatory opinions confirming that certain early products developed using RTDS technologies will be regulated similarly to conventional breeding in both North and South America[143]. Competitive Landscape - The company faces significant competition, with many competitors possessing greater financial and technical resources[16]. - Cibus faces significant competition from major agricultural chemical companies and smaller biotechnology firms, which have greater financial resources and R&D expertise[180]. - Cibus' proprietary technologies are protected by over 500 patents across 26 patent families, with issued patents expected to expire between 2027 and 2040, providing a competitive advantage[138]. Business Model - Cibus' business model involves licensing plant traits to seed companies for royalties, which is a well-established practice in the industry[26]. - The agricultural trait business is driven by productivity traits, addressable acreage, and trait fees, with royalties paid for each unit sold or acre used[92]. - Cibus operates a capital-efficient and highly scalable business model, focusing on R&D and trait development while partnering with leading seed companies for commercialization[186]. Workforce and Culture - As of December 31, 2025, Cibus had 118 full-time employees, with 29 holding Ph.D. degrees, and approximately 89 employees engaged in R&D[189]. - Cibus aims to maintain a diverse workforce, with approximately 57% of its employees holding advanced degrees and nearly half being women[191]. - The company emphasizes employee well-being through competitive compensation and benefits programs, including healthcare and retirement planning[190]. - Cibus' management team has over 300 years of cumulative industry experience, contributing to its scientific breakthroughs and product development[188]. Strategic Partnerships - The company is exploring alternative customer partnerships in high-potential markets such as India, Asia (excluding China), and Latin America[27]. - Cibus is pursuing partner-funded projects in its productivity trait portfolio until it has sufficient capital resources for a more robust development effort[29]. Trait Development - Cibus' gene editing process, RTDS, is designed to produce non-transgenic traits, ensuring that the final products are indistinguishable from those occurring in nature[125]. - Cibus' productivity traits are classified as non-transgenic and are not subject to heightened GMO regulations in key markets including the United States, Canada, Argentina, Chile, and Ecuador[184]. - Cibus' Trait Machine Process significantly accelerates the development and commercialization of new productivity traits, allowing for quick prototyping and scaling into elite germplasm[185].

Financial Position - Cibus reported a cash position of $9.9 million as of December 31, 2025, and expects existing cash to fund operations into late Q3 2026[21]. - Cibus' cash and cash equivalents decreased to $9.923 million as of December 31, 2025, down from $14.433 million a year earlier, a decline of approximately 31.5%[37]. - The company anticipates the need for additional near-term funding to finance its activities, indicating potential challenges in obtaining capital on acceptable terms[31]. Revenue and Loss - Net loss for the quarter ended December 31, 2025, was $31.9 million, an increase from $25.8 million in the same period last year, representing a year-over-year increase of approximately 23.9%[26]. - Total revenue for the quarter was $1.057 million, down from $1.212 million in the same quarter of 2024, reflecting a decrease of approximately 12.8%[41]. - Net loss for 2025 was $132,201, a significant improvement from a net loss of $282,713 in 2024, representing a reduction of approximately 53%[43]. Expenses - R&D expenses decreased to $9.4 million in Q4 2025 from $12.4 million in the previous year, reflecting cost reduction initiatives[21]. - SG&A expenses were reduced to $5.1 million in Q4 2025 compared to $6.8 million in the year-ago period, also due to cost-saving measures[21]. - Total operating expenses increased to $23.631 million from $19.236 million year-over-year, an increase of approximately 22.8%[41]. Assets and Liabilities - Total assets decreased to $305.047 million from $350.069 million year-over-year, a decline of approximately 12.9%[39]. - Total liabilities increased to $283.218 million from $252.238 million, reflecting an increase of approximately 12.3%[39]. Operational Highlights - The company achieved a significant milestone with its first customer payment from the Sustainable Ingredients program in Q4 2025, indicating strong commercial potential[6]. - Cibus' Rice program is on track for targeted launches in 2027 and 2028, with a potential for over $200 million in annual addressable royalties at peak[7]. - Cibus' single-cell editing system has achieved up to 50-70% efficiency, fundamentally changing breeding economics for seed companies[6]. Regulatory and Market Developments - The EU reached a political agreement on New Genomic Techniques legislation, a significant regulatory advancement that Cibus has influenced over the past decade[6]. - Cibus' Trait Machine process was recognized by Fast Company Magazine as one of the most innovative products in 2024, highlighting the company's advancements in gene editing technology[29]. Cash Flow and Financing - Net cash used in operating activities improved from $58,043 in 2024 to $50,591 in 2025, reflecting a decrease of approximately 13%[43]. - Proceeds from issuances of securities increased to $50,100 in 2025 from $43,902 in 2024, marking an increase of about 14%[43]. - Net cash provided by financing activities rose to $46,648 in 2025 compared to $40,598 in 2024, an increase of about 15%[43]. Impairments - Long-lived assets impairment was reported at $9.1 million for Q4 2025, attributed to the planned wind-down of operations at the Roseville facility[21]. - Goodwill impairment decreased from $181,432 in 2024 to $20,950 in 2025, indicating a reduction of about 88%[43].

Core Viewpoint - Cibus, Inc. is set to report its fourth quarter 2025 financial results on March 17, 2026, and will host a conference call to discuss these results and other updates [1]. Group 1: Financial Results Announcement - Cibus will announce its fourth quarter 2025 financial results on March 17, 2026 [1]. - The management team will conduct a conference call and audio webcast at 4:30 p.m. ET on the same day [1]. Group 2: Conference Call Details - Participants can join the conference call using the numbers +1-800-343-5172 (U.S.) and +1-203-518-9856 (International) [2]. - A replay of the call will be available until March 31, 2026, accessible via +1-844-512-2921 (U.S.) and +1-412-317-6671 (International) with the passcode 11160915 [2]. Group 3: Company Overview - Cibus is a leader in developing plant traits that address productivity, yield, and sustainability challenges [4]. - The company utilizes proprietary high-throughput gene-editing technologies to develop traits more efficiently than conventional breeding methods [4]. - Cibus operates as a technology company, licensing its developed traits to seed companies in exchange for royalties [4].

Core Insights - Cibus is participating in a significant research project funded by the UK Government to develop durable resistance to Light Leaf Spot disease in oilseed rape, which has caused yield losses of up to £300 million in recent years [1][3][5] Group 1: Project Overview - The project is part of the Farming Innovation Programme, with Defra investing in mid-stage precision breeding projects to enhance the resilience and productivity of UK agriculture [2][5] - Cibus will utilize its proprietary Rapid Trait Development System™ to create precise gene edits in elite oilseed rape breeding lines, aiming to combat Light Leaf Spot disease [3][4] Group 2: Collaboration and Goals - The LLS-ERASED project involves a consortium of 12 industry and academic partners, targeting the UK's most destructive oilseed rape disease to deliver high-yielding varieties with durable, multi-disease resistance [3][4] - The project aligns with the Genetic Technology (Precision Breeding) Act 2023, positioning England as a global hub for gene-edited crop development [4] Group 3: Funding and Support - The Defra Farming Innovation Programme, in partnership with Innovate UK, will provide at least £21.5 million in funding for 15 innovation projects aimed at developing sustainable crops and supporting farmers [5]